Newstrike Brands (TSXV:HIP) announced an agreement with the Neal Brothers company to create a joint venture for the development of cannabis edibles.

As quoted in the press release:

The joint venture partners will conceive and develop innovative edible cannabis products at Newstrike’s fully-licensed Niagara operations, where an in-house research and development facility is being constructed. Product development and future product brand names will be based on consumer data and insights.

Terms of Agreement

Pursuant to the Joint Venture Agreement, Newstrike and Neal Brothers have incorporated a joint venture entity and have agreed on terms relating to the management and control of the specialty food products company (the “Joint Venture“). The Company and Neal Brothers will contribute proportional capital in the Joint Venture in exchange for a 60 [percent] and a 40 [percent] interest in the Joint Venture, respectively. The Joint Venture will be involved in the procuring, manufacturing, distributing, marketing and selling of certain co-branded specialty food products which will be infused, derived or otherwise include cannabis.

Additional Investment

The Company has also entered into an agreement to acquire a minority interest in Neal Brothers, pursuant to a share purchase agreement (the “SPA” and, together with the Joint Venture Agreement, the “Agreements“). As part of the agreement, Peter and Chris Neal will also provide advisory services to Newstrike with respect to the business of Newstrike.

Click here to read the full press release.


Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less